Bosentan in Children With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to demonstrate that the exposure to bosentan in children with
idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension,
using a pediatric formulation, is similar to that in adults with PAH and to evaluate the
tolerability and safety of a pediatric formulation of bosentan in this patient population.